AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22320714
Drug: 1450 ppm;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1450 ppm; twice a day, plus the 'massage' method once a day
Trial: 21490522
Drug: S-ketamine infusion
RxNorm normalized name: (S)-(-)-ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-ketamine infusion at 2 μg · kg · min for 3 hrs
Trial: 21490522
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion at equivalent rate for 3 hrs
Trial: 22189657
Drug: S-ketamine infusion
RxNorm normalized name: (S)-(-)-ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-ketamine infusion
Trial: 17668562
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment switch
Trial: 17668562
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment switch
Trial: 11125195
Drug: 1,100 ppm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,100 ppm fluoride dentifrice (Winterfresh Gel)
Trial: 9586886
Drug: Interferon alfa
RxNorm normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa 8 million U subcutaneously daily
Trial: 9586886
Drug: Interferon alfa
RxNorm normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa 1 million U subcutaneously daily
Trial: 3132930
Drug: Intravenous lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lipid infusion alone
Trial: 28634748
Drug: Ramucirumab 8
RxNorm normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ramucirumab 8 mg/kg in combination with 80 mg/m2 paclitaxel
Trial: 28634748
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in combination with 80 mg/m2 paclitaxel
Trial: 21122391
Drug: Interleukin-11 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin-11 (50 µg × kg(‐1) × d(‐1))
Trial: 12820332
Drug: Adjuvant autologous
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant autologous tumor cell lysate vaccine
Trial: 9211627
Drug: Isradipine (5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (5mg daily for 4 weeks)
Trial: 2823859
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g of fish oil daily (1.8 g eicosapentaenoic acid)
Trial: 2823859
Drug: Placebo supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo supplement containing olive oil (iso-energetic)
Trial: 16798303
Drug: Oral citrulline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral citrulline (1.9 g/m2 per dose, 5 perioperative doses)
Trial: 9660042
Drug: Oral diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diazepam 0.2 mg/kg
Trial: 9174878
Drug: Oral clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clonidine 3 micrograms/kg
Trial: 29482597
Drug: General Psychiatric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General Psychiatric Management (GPM) treatment for BPD
Trial: 27562743
Drug: Short cycle
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short cycle therapy (5 days on, 2 days off ART)
Trial: 27562743
Drug: Continuous therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous therapy (continuous ART)
Trial: 27562743
Drug: Short cycle
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short cycle therapy
Trial: 22767410
Drug: Transdiagnostic cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdiagnostic cognitive-behavioral group treatment (12 weeks)
Trial: 22767410
Drug: Diagnosis-specific group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diagnosis-specific group Cognitive-Behavioral Therapy (CBT) protocols (12 weeks)
Trial: 9426079
Drug: Inhaled phosphoramidon
RxNorm normalized name: phosphoramidic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled phosphoramidon (10[-5] M)
Trial: 7506155
Drug: Bromeline (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromeline (240 mg/day)
Trial: 30930132
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (20 mg/kg body weight)
Trial: 30930132
Drug: Combined supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined supplementation with nitrate (7 mg/kg body weight) and vitamin C
Trial: 30930132
Drug: Nitrate (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate (7 mg/kg body weight)
Trial: 25901838
Drug: 33-G needle
RxNorm normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 33-G needle
Trial: 25901838
Drug: 30-G needle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-G needle
Trial: 16875654
Drug: Antibiotics (metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (metronidazole 250 mg and erythromycin 250 mg at 20 to 24 weeks of gestation 3 times daily for 7 days and metronidazole 250 mg and ampicillin 500 mg every 4 hours during labor)
Trial: 12548304
Drug: Soya scones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soya scones (120 mg/day of isoflavones)
Trial: 10861339
Drug: Tribulus terrestris
RxNorm normalized name: TRIBULUS TERRESTRIS
DrugBank: Tribulus terrestris (DB14358)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tribulus terrestris (3.21 mg per kg body weight daily)
Trial: 3703176
Drug: PK 8165
RxNorm normalized name: Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PK 8165 (50, 100, 150 mg)
Trial: 3703176
Drug: Control session
RxNorm normalized name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 100 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 60 mg in 1 mL TOPICAL LOTION [SESSION SAVERS SUNSCREEN BROAD SPECTRUM SPF 30 WATER RESISTANT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control session (no treatment)
Trial: 29926988
Drug: Galantamine 8
RxNorm normalized name: galantamine 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine 8 mg/day
Trial: 28069279
Drug: Masitinib (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Masitinib (6 mg/kg per day over 24 weeks)
Trial: 26308758
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy (20 mg of omeprazole, 1g of amoxicillin, 500 mg of metronidazole, and 400 mg of bismuth compound for 7 days)
Trial: 26308758
Drug: Pylorex Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pylorex Plus (500 mg for 15 days)
Trial: 18713259
Drug: Adjunctive antimicrobial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive antimicrobial photodynamic therapy (aPDT)
Trial: 18713259
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (with and without adjunctive aPDT)
Trial: 16365181
Drug: Chemotherapy in
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy in CALGB studies for extensive-stage small-cell lung cancer
Trial: 12941995
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination therapy regimen 1
Trial: 12941995
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination therapy regimen 2
Trial: 11055467
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (beta-blockers and diuretics)
Trial: 31630249
Drug: Intra-esophageal injection
RxNorm normalized name: somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-esophageal injection of 10 mL of thickened water at 10 mL/s
Trial: 31630249
Drug: Intra-esophageal injection
RxNorm normalized name: somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-esophageal injection of 3 mL of thickened water at 10 mL/s
Trial: 31630249
Drug: Intra-esophageal injection
RxNorm normalized name: somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-esophageal injection in the upper region
Trial: 26651478
Drug: Blended cognitive
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blended cognitive behavioural therapy
Trial: 26651478
Drug: Face-to-face cognitive
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face-to-face cognitive behavioural therapy
Trial: 17926617
Drug: Electroacupuncture (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA) plus behavior therapy
Trial: 14693413
Drug: Acarbose (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose (titrated to a maximum of 100mg three times daily)
Trial: 14693413
Drug: Tolbutamide (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolbutamide (titrated to a maximum of 2000 mg in three doses)
Trial: 11204938
Drug: Novofem (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novofem (1 mg estradiol + 1 mg norethisterone acetate)
Trial: 11204938
Drug: Activelle (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activelle (1 mg estradiol + 0.5 mg norethisterone acetate)
Trial: 7530064
Drug: N,G‐nitro‐L‐arginine methyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N,G‐nitro‐L‐arginine methyl ester (L‐NAME)
Trial: 31126277
Drug: Complex on-site
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex on-site intervention including physician visits, nursing staff involvement, computerized documentation system (CoCare Cockpit), joint trainings and audits, structured treatment paths, after-hours medical care availability.
Trial: 31126277
Drug: Care/treatment as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Care/treatment as usual (control group).
Trial: 24918474
Drug: Prescription of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription of Physical Activity (PPA)
Trial: 23743809
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment with indapamide sustained release 1.5 mg +/- perindopril 2-4 mg
Trial: 9186346
Drug: Sialyl Lewis(x)
RxNorm normalized name: sialyl Lewis A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sialyl Lewis(x) molecules
Trial: 7903213
Drug: Tertatolol 5
RxNorm normalized name: tertatolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tertatolol 5 mg once daily
Trial: 29223479
Drug: Pertuzumab plus
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pertuzumab plus trastuzumab with anthracycline-containing chemotherapy (FEC)
Trial: 29223479
Drug: Pertuzumab plus
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pertuzumab plus trastuzumab with anthracycline-free chemotherapy (docetaxel)
Trial: 27177615
Drug: Chlorella (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorella (5 g/d)
Trial: 11465710
Drug: Diclofenac +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac + Misoprostol (75 mg diclofenac + 200 microg misoprostol twice daily for 6 weeks)
Trial: 11465710
Drug: Acetaminophen (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (1,000 mg acetaminophen 4 times daily for 6 weeks)
Trial: 31607603
Drug: Standard-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose oral Rotarix vaccine
Trial: 31607603
Drug: High-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oral Rotarix vaccine
Trial: 30076113
Drug: IV rt-PA
RxNorm normalized name: rt-PA
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV rt-PA treatment for patients with body weight >100 kg
Trial: 26437613
Drug: Chamomile tea
RxNorm normalized name: Chamomile Tea
DrugBank: Chamomile (DB14357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chamomile tea (3 g/150 mL hot water) 3 times per day immediately after meals for 8 weeks
Trial: 3100007
Drug: Diltiazem 360
RxNorm normalized name: dilTIAZem 360 mg/24 hours oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 360 mg
Trial: 21423055
Drug: n‐3FA supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n‐3FA supplements (stopped an average of 2.3 days before surgery)
Trial: 21423055
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no n‐3FA supplements)
Trial: 21423055
Drug: n‐3FA supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n‐3FA supplements
Trial: 15747149
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 2D and 3D ultrasound
Trial: 8684301
Drug: Exposure to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure to MMMF and other agents
Trial: 361068
Drug: Bromocriptine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (2.5 mg twice daily) for 4 to 17 weeks
Trial: 361068
Drug: Placebo (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (one tablet twice daily) for 4 to 12 weeks
Trial: 28478317
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (group B)
Trial: 15074084
Drug: Yangxue Qingnao
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yangxue Qingnao granule (YXQN) plus conventional medical treatment
Trial: 15074084
Drug: Conventional medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional medical treatment alone
Trial: 8198932
Drug: [S]-leucovorin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: [S]-leucovorin (300 mg m-2)
Trial: 8198932
Drug: rac-leucovorin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rac-leucovorin (600 mg m-2)
Trial: 2822879
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg enalapril daily
Trial: 2822879
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg atenolol and 10 mg enalapril (low-dose combination)
Trial: 29862395
Drug: Dietary supplement
RxNorm normalized name: dietary supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplement based on Lippia citriodora and Hibiscus sabdariffa polyphenolic extracts
Trial: 26257041
Drug: Upper airway
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Upper airway stimulation (UAS) system implantation, first implant (n=22)
Trial: 26257041
Drug: Upper airway
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Upper airway stimulation (UAS) system implantation, fifth implant (n=10)
Trial: 24184147
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) in adults (n=54)
Trial: 24184147
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) in children (n=99)
Trial: 24184147
Drug: Subcutaneous immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous immunotherapy (SCIT) in adults
Trial: 23155007
Drug: W→G
RxNorm normalized name: Warfarin to Glyburide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: W→G
Trial: 23155007
Drug: G→B
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: G→B
Trial: 23155007
Drug: B→G
RxNorm normalized name: Betamethasone-17-valerate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B→G
Trial: 11121919
Drug: Oral menadiol
RxNorm normalized name: MENADIOL
DrugBank: Menadiol diphosphate (DB14650)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral menadiol 20 mg o.d. for 3 days (n=12)
Trial: 11121919
Drug: Intravenous phytomenadione
RxNorm normalized name: phytomenadione
DrugBank: Phylloquinone (DB01022)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous phytomenadione 10 mg o.d. for 3 days (n=14)
Trial: 9125681
Drug: Lacidipine, 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacidipine, 4 mg daily
Trial: 1607091
Drug: Oral lavage
RxNorm normalized name: lovage oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral lavage plus enemas
Trial: 1607091
Drug: Oral lavage
RxNorm normalized name: lovage oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral lavage alone
Trial: 2984617
Drug: Neo Sampoon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neo Sampoon tablets
Trial: 3689613
Drug: i.v. cimetidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. cimetidine 200 mg
Trial: 3689613
Drug: i.v. ranitidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. ranitidine 50 mg
Trial: 31058387
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy in septic patients
Trial: 28620941
Drug: 3 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 × 75 g sucrose per day for 14 days
Trial: 23786500
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care intervention through hospital pharmacists
Trial: 22981342
Drug: 5-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day course of amoxicillin/clavulanic acid 1.2g intravenously every 8h for 24h, followed by 625 mg orally every 8h for 4 days
Trial: 22981342
Drug: 1-day course
RxNorm normalized name: ESTRADIOL BENZOATE 1 kg in 1 kg POWDER [Estradiol Benzoate Coarse Grade]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-day course of amoxicillin/clavulanic acid 1.2g intravenously every 8h for 24h, followed by placebo orally at the same time intervals
Trial: 21544000
Drug: General +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General + Specific Warm-Up (G + SWU)
Trial: 18434903
Drug: N-acetylcysteine 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine 600 mg orally twice a day, from preoperative day 1 to postoperative day 1
Trial: 11075310
Drug: RGD891 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RGD891 (60 micrograms/kg bolus dose + 336 micrograms/kg 8-h infusion)
Trial: 11075310
Drug: RGD891 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RGD891 (various intravenous regimens)
Trial: 9146820
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg naloxone
Trial: 9146820
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg buprenorphine and 0.1 mg naloxone in combination
Trial: 8398324
Drug: STADMAX (scopolamine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STADMAX (scopolamine, tavegyl, ativan, dexamethasone, high dose maxolon)
Trial: 8398324
Drug: SAD (serenace,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAD (serenace, ativan, dexamethasone, low dose maxolon)
Trial: 30244882
Drug: Dose escalation
RxNorm normalized name: PALFORZIA Initial Dose Escalation KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation above 60 Gy EQD2
Trial: 30244882
Drug: Concurrent or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent or sequential chemoradiation or radiation only
Trial: 24855132
Drug: Cervical spine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical spine and vestibular rehabilitation (treatment group)
Trial: 20626608
Drug: Sildenafil 100
RxNorm normalized name: sildenafil 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 100 mg or 50 mg
Trial: 19039629
Drug: Micafungin 150
RxNorm normalized name: micafungin 150 MG in 150 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micafungin 150 mg
Trial: 9332510
Drug: Fluconazole 400
RxNorm normalized name: fluconazole 400 MG in 200 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 400 mg
Trial: 16866136
Drug: Tribendimidine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tribendimidine (400 mg)
Trial: 16866136
Drug: Tribendimidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tribendimidine (300 mg)
Trial: 16866136
Drug: Tribendimidine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tribendimidine (400 mg/day for 3 days)
Trial: 16866136
Drug: Albendazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (400 mg/day for 3 days)
Trial: 16866136
Drug: Tribendimidine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tribendimidine (200 mg)
Trial: 16866136
Drug: Albendazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (200 mg)
Trial: 8752294
Drug: Monovalent WC3
RxNorm normalized name: rotavirus, monovalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent WC3 reassortant vaccine (serotype G1)
Trial: 8752294
Drug: Quadrivalent WC3
RxNorm normalized name: HPV, quadrivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent WC3 reassortant vaccine (HRV G1, G2, G3, and P[8])